A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin and Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naive Patients With Type 2 Diabetes Mellitus.

Trial Profile

A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin and Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naive Patients With Type 2 Diabetes Mellitus.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms VERIFY
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Oct 2014 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019 as reported by ClinicalTrials.gov.
    • 01 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 19 May 2014 The study design published online in Diabetic Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top